Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection
- PMID: 11240691
- DOI: 10.1046/j.1525-1438.2000.010004305.x
Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection
Abstract
The objective of this paper was to analyze the 5-year survival rate and prognostic factors for stage Ib and IIa cervical cancer treated by radical hysterectomy. A total of 366 patients with invasive cervical cancer treated by radical hysterectomy from June 1985 to June 1994 at Chonnam National University Hospital, Kwangju, Korea were retrospectively analyzed. Survival analysis was performed using the Kaplan-Meier estimator. Multivariate analysis was performed using the Cox proportional hazards regression model. The overall 5-year survival rate was 92% in stage Ib and 87% in stage IIa. Factors assessed for prognostic value included age, FIGO stage, cell type, tumor size, depth of invasion, lymphovascular space invasion (LVSI), and pelvic lymph node metastases (LNM). In the multivariate analysis, age, cell type, and lymph node metastases were independent predictors of survival. Lower survival was associated with age greater than 50 years, adenocarcinoma, and presence of lymph node metastases. The higher survival rates in patients with single lymph node involvement or lymph node metastases below the level of the common iliac nodes (85 and 84.6%, respectively) versus multiple or extrapelvic lymph node metastases (50 and 20%, respectively) were statistically significant (P < 0.01). In conclusion, patients who had lymph node metastases, adenocarcinoma, and were older than 50 years had a poorer survival rate. Such patients require more intense postoperative treatment and closer surveillance. Low-risk patients with a single lymph node metastasis below the level of the common iliac nodes may benefit from thorough lymphadenectomy without adjuvant therapy to prevent unpleasant complications.
Similar articles
-
Multivariate analysis of histopathologic prognostic factors for invasive cervical cancer treated with radical hysterectomy and systematic retroperitoneal lymphadenectomy.Acta Obstet Gynecol Scand. 2002 Dec;81(12):1144-51. doi: 10.1034/j.1600-0412.2002.811208.x. Acta Obstet Gynecol Scand. 2002. PMID: 12519111
-
Risk factors for recurrence in patients with stage IB, IIA, and IIB cervical carcinoma after radical hysterectomy and postoperative pelvic irradiation.Obstet Gynecol. 1996 Aug;88(2):274-9. doi: 10.1016/0029-7844(96)00145-7. Obstet Gynecol. 1996. PMID: 8692515
-
Lack of effect of tumor size on the prognosis of carcinoma of the uterine cervix Stage IB and IIA treated with preoperative irradiation and surgery.Int J Radiat Oncol Biol Phys. 1999 Oct 1;45(3):645-51. doi: 10.1016/s0360-3016(99)00217-5. Int J Radiat Oncol Biol Phys. 1999. PMID: 10524418
-
Cervical cancer: combined modality therapy.Cancer J. 2001 Jul-Aug;7 Suppl 1:S47-50. Cancer J. 2001. PMID: 11504285 Review.
-
Effect of the Number of Removed Lymph Nodes on Survival in Patients with FIGO Stage IB-IIA Cervical Squamous Cell Carcinoma following Open Radical Hysterectomy with Pelvic Lymphadenectomy: A Retrospective Cohort Study.J Oncol. 2021 Apr 14;2021:6201634. doi: 10.1155/2021/6201634. eCollection 2021. J Oncol. 2021. PMID: 33936201 Free PMC article. Review.
Cited by
-
A score combining baseline neutrophilia and primary tumor SUVpeak measured from FDG PET is associated with outcome in locally advanced cervical cancer.Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):187-195. doi: 10.1007/s00259-017-3824-z. Epub 2017 Sep 15. Eur J Nucl Med Mol Imaging. 2018. PMID: 28916879
-
Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer.Cochrane Database Syst Rev. 2011 Apr 13;(4):CD008217. doi: 10.1002/14651858.CD008217.pub2. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2013 Mar 28;(3):CD008217. doi: 10.1002/14651858.CD008217.pub3. PMID: 21491407 Free PMC article. Updated.
-
Japan Society of Gynecologic Oncology guidelines 2017 for the treatment of uterine cervical cancer.Int J Clin Oncol. 2019 Jan;24(1):1-19. doi: 10.1007/s10147-018-1351-y. Epub 2018 Oct 5. Int J Clin Oncol. 2019. PMID: 30291468
-
Present status of sentinel lymph node biopsy in cervical cancer.Rep Pract Oncol Radiother. 2018 Nov-Dec;23(6):495-502. doi: 10.1016/j.rpor.2018.04.004. Epub 2018 May 9. Rep Pract Oncol Radiother. 2018. PMID: 30534012 Free PMC article. Review.
-
Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.Cochrane Database Syst Rev. 2021 Mar 4;3(3):CD013348. doi: 10.1002/14651858.CD013348.pub2. Cochrane Database Syst Rev. 2021. PMID: 33661538 Free PMC article.
LinkOut - more resources
Full Text Sources